Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.
Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, DI Cesare A, Panduri S, Pescitelli L, Trovato E, Prignano F.
Manzo Margiotta F, et al. Among authors: di cesare a.
Ital J Dermatol Venerol. 2024 Feb;159(1):64-65. doi: 10.23736/S2784-8671.23.07648-X. Epub 2023 Nov 23.
Ital J Dermatol Venerol. 2024.
PMID: 37997317
No abstract available.